Food Advertising, Labeling, and Litigation Conference: For the Food and Dietary Supplement Industries
Crowell & Moring LLP
1001 Pennsylvania Ave. NW
Washington, DC 20004
While the 2018 Farm Bill declassified hemp and hemp-derived products as a Schedule I controlled substance, it expressly preserved FDA’s authority to regulate products containing cannabis or related compounds. However, this has not stopped the proliferation of CBD-containing food, beverage, and dietary supplement products becoming available on the market, both online and in retail stores. This panel will provide an overview FDA actions regarding cannabis products, what upcoming changes may be on the horizon, and strategies for managing risks in an evolving regulatory landscape.
Allison Fulton, Partner, Sheppard Mullin, Richter & Hampton LLP
Marc C. Sanchez, Regulatory Counsel, CIHCC, LLC (d/b/a FDA Atty)
Sharon Mayl, Senior Advisor for Policy, FDA (Invited)
Click here for more information and registration.